Publications

Nikita Baclig, Andrew Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyn Face, Madhuri Chengappa, Saliha Chaudhry, Dame Idossa, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Anne Blaes, Hope S. Rugo, Melissa Lechner, Kelly E. McCann. Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID:

Laura A. Huppert, Kelsey Kuwahara, Maggie Zhou, Mia Salans, Samantha Fisch, Jo Chien, Melanie Majure, Hope Rugo, Lauren Boreta, Steve E. Braunstein, Ramin A. Morshed, Harish N. Vasudevan, Michelle E. Melisko. Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study. Clinical Cancer Research. 2025. PMID:

Fukuda K, Nanjo S, Takeuchi S, Chakrabarti T, Brown T, Dev Sahadevan SW, Arai S, Sato S, Kotani H, Nishiyama A, Sakaguchi H, Ohtsubo K, Taniguchi H, Blakely CM, Bivona TG, Yano S. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025. PMID: 40518016

Samantha Fisch, Joshua Chin, Laura Quintal, Melanie Majure, Michelle Melisko, Jo Chien, Hope S. Rugo, Laura A. Huppert. Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer. Clinical Cancer Research. 2025. PMID:

Alexis LeVee, Saya Jacob, Samantha Fisch, Carolyne Face, Madhuri Chengappa, Saliha Chaudhry, Nikita Baclig, Andrew Soliman, Nora Ruel, Megan Wong, Karen Tsai, Irene Kang, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Melissa Lechner, Dame Idossa, Anne Blaes, Kelly McCann, Hope S. Rugo, Joanne Mortimer. Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Stevers NO, Kim S, Yuan JB, Barger CJ, Hong C, Lenzo O, McKinney AM, Wu SH, Lee YJ, Kwok DW, Suwala AK, Appin CL, Gordan JD, Molinaro AM, Song JS, Costello JF. The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible. Molecular cell. 2025. PMID: 40513567

Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 40504161

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40504618

Gallagher TJ, Lin ME, Kim I, Kwon DI, Kokot NC. Reduced Mortality With Treatment of Anxiety and Depression Among Head and Neck Cancer Survivors. The Laryngoscope. 2025. PMID: 40497673

Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, Pang J, Toskic D, Scalia S, Ma X, Lee LX, Wong SW, Chung A, Tuchman SA, Fogaren T, Coady Lyons N, Varga C, Lentzsch S, Comenzo RL. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of clinical medicine. 2025. PMID: 40565890

Epstein L, Weiner AC, Verma A, Saedi M, Carnevale J, Marson A, Engelhardt BE. Live-cell analyses with unsegmented images to study cancer cell response to modified T cell therapy. bioRxiv : the preprint server for biology. 2025. PMID: 40502136

Suri I, Kwon D, Suthakaran S, Javier J, Syed M, Hu J, Carr M, Steinberger J. Lumbar spine deformation between prone and supine CTs. Neurosurgical review. 2025. PMID: 40481280

Beckermann KE, Shah NJ, Campbell MT, Haas NB, Nelson A, Ornstein MC, Mao S, Keshava-Prasad HS, Hammers H, Gao X, Gourdin T, George S, Hoimes CJ, Hussain A, Jonasch E, Rini BI, Voss MH. Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma. The oncologist. 2025. PMID: 40549043

Liao N, Li C, Gradishar WJ, Klimberg VS, Roshal JA, Yuan T, Agarwala SS, Valero VK, Swain SM, Margenthaler JA, Rubio IT, Hurvitz SA, Geyer CE, Lin NU, Rugo HS, Zhang G, Liu N, Balch CM. Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients. JCO clinical cancer informatics. 2025. PMID: 40466030

Miller J, Cuby J, Hall SM, Stitzer M, Kushel M, Appiah D, Vijayaraghavan M. Corrigendum to "Tobacco use behaviors and views on engaging in clinical trials for tobacco cessation among individuals who experience homelessness" [Contemporary Clinic. Trials Commun. 32 (2023) 101094]. Contemporary Clinical Trials Communications. 2025. PMID: 40727927

Rugo HS, Xu B, Dasgupta A, Kaushik A, Verret W, Singh B. A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers. 2025. PMID: 40507364

Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature reviews. Cancer. 2025. PMID: 40461793

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40459151

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO open. 2025. PMID: 40460679